Home Today's Paper Most Popular Video Gallery Photo Gallery
Subscription Blog Signin Register
Logo
Friday, August 17, 2018 11:10:03 PM
Follow Us On: Facebook Twitter Twitter Twitter Twitter

Innovation doesn't happen by accident

By
13th-May-2018       
Comments
Share your thought
Post a comment »
Read all () »

Mark J. Alles :
But today, some question the real impact of innovation in healthcare and if it is worth it. The European Commission is currently considering modifications to the intellectual property framework in Europe, partially in response to the chronic sustainability and affordability challenges among healthcare systems. But some of these proposals likely put the healthier future we all envision at risk by stifling innovation that is critical to economic growth and improving healthcare.
There is no doubt that we face challenges in healthcare, but solutions must address these challenges while still fostering growth and progress. Too often, this debate is reduced to a single issue: the perceived high cost of medicines. However, this is a massive oversimplification of a much bigger picture. The complexities of managing healthcare expenditures in Europe while driving health gains and economic prosperity over the long term are great. In this effort, incentives must encourage innovation, not deter it.  Understanding the facts is an important start:
First, medications account for less than 15% of overall EU healthcare spending, and several recent studies refute the long-held belief that medicine costs are rising uncontrollably. A recent study on the projected impact of medicines in the UK, France, Germany, Spain and Italy shows that the net pharmaceutical expenditure is projected to rise just 1-2% over the next five years, in line with projected economic growth. These modest increases should not be blamed for long-term sustainability issues across the entire healthcare system.
Second, we must consider the role of today's intellectual property framework, which aligns appropriate incentives to drive innovation with continuing value for generations through the availability of lower-cost generic medicines when novel medicines lose their exclusivity. Of course, we need to collaborate on solutions for short-term affordability issues, and the biopharmaceutical sector has shown its willingness and ability to advance positive solutions. But we must also preserve what is working: today's incentives framework stimulates transformative research, ensures competition, and rewards innovators for investing in the challenging research required to discover new medicines.
The incentives framework in the EU has proven itself, successfully driving innovation and reducing the financial impact of diseases across many therapeutic areas. For example, in rare diseases, the Orphan Regulation was introduced precisely to spur innovation in some of the most difficult-to-treat diseases affecting small numbers of people. As a result, people with life-threatening and seriously debilitating rare diseases in Europe have benefitted from significant investment and a dramatic increase in available medicines to treat their conditions - from just 8 medicines for orphan indications 15 years ago to more than 140 medicines today.
At Celgene, more than ten years of research focused on multiple myeloma, a rare, life-threatening, blood cancer, allowed us to develop three novel medicines that have helped contribute - along with other therapies - to the doubling of the five-year survival rate for patients living with multiple myeloma.
The first of Celgene's multiple myeloma medicines will lose market exclusivity later this year, joining the medicine cabinet of generics that will continue to deliver value for society at low costs for as long as they remain necessary for the treatment of a specific disease.
Beyond offering a tested and proven framework, incentives are also responsible for encouraging investment in high-risk research that has the potential to one day cure diseases like cancer, dementia and heart disease. At Celgene, we invest nearly 40% of our revenues on average back into R&D annually. This investment is risky. In fact, we recently stopped clinical studies on a compound for Crohn's Disease, because our investigational medicine did not show enough impact on the disease to support continued clinical development in this setting. We will never recover our investment on this compound, but we took this risk because patients need new and better options. This decision and others like it are possible because we currently work within an innovation framework that rewards those successful medicines that do make a difference for patients.
Finally, we are very aware of how innovation incentives impact industrial policy, including job creation and economic investment. For instance, Celgene, a U.S.-based company, chose to establish operations in Europe 11 years ago because of the confidence created by the EU incentives environment. Without such support, Celgene may not have established operations in Europe, that brought more than 2000 jobs, significant R&D investment, and, of course, innovative medicines to patients in Europe.
The EU's decisions about the future of incentives for biopharmaceutical innovation will have broad implications. Global competition to attract investments is increasing.  Maintaining a competitive environment is critical to continue attracting investment as well as stimulating the creation of new ones. And while medical technologies have advanced over the past 30 years, reimbursement models have not. Appropriate reimbursement models can also align the right incentives and allow us to seize the opportunities that science is delivering.
All that to say, innovation doesn't happen by accident; it is the result of high-risk, long-term investment which is only possible when companies and investors are confident that they will be able to make reasonable returns if successful. The limited period of exclusivity within today's incentives framework is key to this virtuous cycle of investment. With the right incentives in place, biopharmaceutical companies can continue to invest in R&D and enable broader access to innovative medicines that can have a life-changing impact on patients and the healthier world we are creating together.

(Mark J. Alles is Chairman and CEO of Celgene).

Tariff
Add Rate

News Archive

Inside The New Nation

Football »

Los Angeles FC midfielder Eduard Atuesta (top) leaps over Real Salt Lake defender Justen Glad during the second half of an MLS soccer match in Los Angeles on Wednesday.


Cricket »

India mourns cricket 'renaissance man' Wadekar Sir


AFP, Mumbai : Indian cricket heroes on Thursday paid tribute to Ajit Wadekar, who led the country to their first series triumphs in England and the West Indies, following his death at the age of 77."He will always be remembered as the 'renaissance man' of Indian cricket," said Board of ...

Editorial »

No improvement in Hajj management


A TOTAL of 606 people could not fly to Saudi Arabia to perform Hajj this year for various reasons, including negligence of hajj agencies, said Religious Affairs Minister on Wednesday. He said a number of complaints have been received against some agencies and action will be taken against them after ...

Entertainment »

Deepika features in the September issue of Vogue Magazine


Actress Deepika Padukone has now been featured by the prestigious Vogue magazine in their September issue. Deepika Padukone has featured in the issue alongside 33 other achievers who are known for effecting change and leading conversations wherever their career has taken them. Deepika is the only Indian personality to get ...

City »

PM pays tributes to Samakal Editor Golam Sarwar


Prime Minister Sheikh Hasina on Thursday paid rich tributes to veteran journalist and daily Samakal Editor Golam Sarwar.  On behalf of the premier, her Press Secretary Ihsanul Karim placed a wreath on the coffin of Golam Sarwar on the Jatiya Press Club premises here on Thursday afternoon.Earlier, a namaz-e-janaza of ...

International »

US newspapers hit back at Trump, defend free press


AFP, Washington US newspapers big an:d small hit back Thursday at President Donald Trump's relentless attacks on the news media, launching a coordinated campaign of editorials stressing the importance of a free press.Leading the charge was The Boston Globe, which had issued an appeal for this drive-accompanied by the hashtag ...

Chittagong »

CCC Mayor A J M Nasir Uddin offering Munajat at a Milad, Dao Mahfil and discussion meeting in observance of the National Mourning Day recently.


.

Editorial »

Problems are not solved but multiplied by politically motivated arrests and cases


AGAINST the backdrop of quota reform movement, a second-year student of Social Science at Eden College Lutfur Nahar Luma was arrested from her grandfather's house in Belkuchi upazila of Sirajganj district in the small hours of Wednesday. Police said the cyber crime unit of the Counter Terrorism and Transnational Crime ...

Sports »

Federer opens with win over Gojowczyk, Kvitova ousts Williams


AFP, Cincinnati :Roger Federer began his US Open preparation with a quick 6-4, 6-4 defeat of Peter Gojowczyk in his first ATP Cincinnati Masters appearance since 2015.The 20-time Grand Slam champion, who turned 37 last week, is pacing his tennis year, playing a limited schedule and skipping events when he ...

Entertainment »

Kajol’s over-protective mother act steals the show


The makers of the Kajol starrer Helicopter Eela have dropped a goofy number from the film that depicts Kajol’s over-protective character in the film. Amit Trivedi’s composition has an upbeat melody and has been rendered by Ronit Sarkar. The peppy number opens with Kajol as Eela spying on her son ...

Entertainment »

Ishita`s play, telefilm in Eid


Sheikh Arif Bulbon :When Ishita won the hearts of many viewers during that time they remained very much eager to watch Ishita’s acting on the screen. But day by day, Ishita started to leave acting. However, viewers still show their keen interest to enjoy Ishita’s acting. She will be seen ...

International »

Trump calls sacked White House aide a


Reuters, Washington  :US President Donald Trump on Tuesday lashed out at former White House aide Omarosa Manigault Newman, calling her a "dog" as his fellow former reality TV star continued to publicly release recordings from her time in Trump's orbit.Their escalating feud was sparked by the release of a tell-all ...

Editorial »

Bangabandhu a great leader of the people and for the people


THE nation mourns the 43rd Shahadat Anniversary of Bangabandhu Sheikh Mujibur Rahman today with prayers and solemnity all over the country. He was assassinated with almost all of his family members in the wee hours of that fateful night at his home in the city. It was a night of ...

Editorial »

Our migrants are being defrauded and harassed in Malaysia but govt remains mum


SOME 270 Bangladeshi workers have allegedly been defrauded of over Tk 3.6 crore by an agent over securing valid work permits under the Malaysian rehiring programme. The Bangladeshi nationals had handed over their passports, other relevant documents and paid between Tk 144,000 and Tk 160,000 each to the agent for ...

Sports »

U.S. swimmer Katie Ledecky teaches Japanese elementary and junior high school students at an event in Tokyo on Tuesday. The 21-year-old American, fresh off a five-medal performance at the Pan Pacific Championships in Tokyo, answered questions about her career and training routine before jumping into the pool with more than 100 star-struck Japanese elementary and junior high school students to give them tips.


.

 
Items that you save may be read at any time on your computer, iPad, iPhone or Android devices.
 
Are you new to our website? Do you have already an account at our website?
Create An Account Log in here
Email this news to a friend or like someone
Email:
Write a comment to this news